These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2604981)

  • 1. The rectal administration of MS Contin: clinical implications of use in end stage cancer.
    Maloney CM; Kesner RK; Klein G; Bockenstette J
    Am J Hosp Care; 1989; 6(4):34-5. PubMed ID: 2604981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
    Gourlay GK
    Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer pain management with a controlled-release oral morphine preparation.
    Lapin J; Houde RW; Kaiko RF; Coyle N; Rogers A; Foley KM
    J Pain Symptom Manage; 1989 Sep; 4(3):146-51. PubMed ID: 2778362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-investigator clinical evaluation of oral controlled-release morphine (MS Contin tablets) administered to cancer patients.
    Lazarus H; Fitzmartin RD; Goldenheim PD
    Hosp J; 1990; 6(4):1-15. PubMed ID: 2088995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with a controlled-release oral morphine for cancer pain management.
    Kim BS; Chung HC
    Postgrad Med J; 1991; 67 Suppl 2():S82-6. PubMed ID: 1758823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical survey of controlled-release morphine sulphate for cancer pain relief in a Japanese hospice.
    Tsuneto S; Hayashi A; Miyazaki M; Kashiwagi T
    Postgrad Med J; 1991; 67 Suppl 2():S79-81. PubMed ID: 1758822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for the use of MS Contin tablets in the management of cancer pain.
    Warfield CA
    Postgrad Med J; 1991; 67 Suppl 2():S9-12; discussion S13. PubMed ID: 1758825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of sustained-release morphine in a hospice setting.
    Sherman LM
    Pharmatherapeutica; 1987; 5(2):99-102. PubMed ID: 3659062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain.
    De Conno F; Ripamonti C; Saita L; MacEachern T; Hanson J; Bruera E
    J Clin Oncol; 1995 Apr; 13(4):1004-8. PubMed ID: 7707099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients.
    Portenoy RK; Maldonado M; Fitzmartin R; Kaiko RF; Kanner R
    Cancer; 1989 Jun; 63(11 Suppl):2284-8. PubMed ID: 2720577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of morphine sulfate (MS Contin) in patients with burns: a pilot study.
    Alexander L; Wolman R; Blache C; Grandy RP; Dyess D; Luterman A
    J Burn Care Rehabil; 1992; 13(5):581-3. PubMed ID: 1452594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
    Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
    Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients.
    Goughnour BR; Arkinstall WW; Stewart JH
    Cancer; 1989 Jun; 63(11 Suppl):2294-7. PubMed ID: 2720578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design.
    Cundiff D; McCarthy K; Savarese JJ; Kaiko R; Thomas G; Grandy R; Goldenheim P
    Cancer; 1989 Jun; 63(11 Suppl):2355-9. PubMed ID: 2720581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of controlled-release oral morphine (MS Contin) in an advanced cancer hospital.
    Brescia FJ
    J Pain Symptom Manage; 1987; 2(4):193-8. PubMed ID: 2444659
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term rectal administration of high-dose sustained-release morphine tablets.
    Walsh D; Tropiano PS
    Support Care Cancer; 2002 Nov; 10(8):653-5. PubMed ID: 12436225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic efficacy and potency of two oral controlled-release morphine preparations.
    Bloomfield SS; Cissell GB; Mitchell J; Barden TP; Kaiko RF; Fitzmartin RD; Grandy RP; Komorowski J; Goldenheim PD
    Clin Pharmacol Ther; 1993 Apr; 53(4):469-78. PubMed ID: 8477564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine at gramme doses: kinetics, dynamics and clinical need.
    Smith KJ; Miller AJ; McKellar J; Court M
    Postgrad Med J; 1991; 67 Suppl 2():S55-9. PubMed ID: 1758817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
    Thirlwell MP; Sloan PA; Maroun JA; Boos GJ; Besner JG; Stewart JH; Mount BM
    Cancer; 1989 Jun; 63(11 Suppl):2275-83. PubMed ID: 2720576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of dosing guidelines for the use of oral controlled-release morphine (MS Contin tablets).
    Warfield CA
    Cancer; 1989 Jun; 63(11 Suppl):2360-4. PubMed ID: 2720582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.